CINECA IRIS Institutional Research Information System

TACITO, ALESSIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.306
EU - Europa 2.960
AS - Asia 1.721
SA - Sud America 201
AF - Africa 125
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.319
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.207
IT - Italia 1.531
CN - Cina 528
SG - Singapore 445
SE - Svezia 431
DE - Germania 354
HK - Hong Kong 252
VN - Vietnam 178
BR - Brasile 175
GB - Regno Unito 133
BG - Bulgaria 105
IN - India 91
FR - Francia 77
CI - Costa d'Avorio 74
CA - Canada 71
AT - Austria 67
RU - Federazione Russa 63
TR - Turchia 62
NL - Olanda 56
JP - Giappone 52
FI - Finlandia 44
SN - Senegal 22
BD - Bangladesh 21
IQ - Iraq 15
PL - Polonia 15
BE - Belgio 14
MX - Messico 12
UA - Ucraina 12
ZA - Sudafrica 11
IR - Iran 10
AR - Argentina 8
ES - Italia 8
TW - Taiwan 8
GR - Grecia 7
ID - Indonesia 7
PK - Pakistan 7
CR - Costa Rica 6
HU - Ungheria 6
RO - Romania 6
CH - Svizzera 5
KR - Corea 5
MA - Marocco 5
UZ - Uzbekistan 5
AU - Australia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
EC - Ecuador 4
IL - Israele 4
MY - Malesia 4
RS - Serbia 4
SA - Arabia Saudita 4
VE - Venezuela 4
AL - Albania 3
AZ - Azerbaigian 3
EG - Egitto 3
IE - Irlanda 3
JM - Giamaica 3
JO - Giordania 3
PT - Portogallo 3
TH - Thailandia 3
BH - Bahrain 2
BY - Bielorussia 2
CL - Cile 2
CO - Colombia 2
DK - Danimarca 2
GT - Guatemala 2
KE - Kenya 2
LT - Lituania 2
PA - Panama 2
PE - Perù 2
PS - Palestinian Territory 2
PY - Paraguay 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MM - Myanmar 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.319
Salva come PNG Salva come JPEG
Città #
Ashburn 400
Hong Kong 243
Singapore 240
Woodbridge 240
Fairfield 231
Dallas 230
Milan 200
Chandler 183
Santa Clara 180
San Jose 162
Houston 135
Ann Arbor 131
Shanghai 112
Beijing 107
Sofia 103
Seattle 96
Cambridge 86
Rome 80
Wilmington 79
New York 75
Abidjan 74
Vienna 61
Florence 57
Ho Chi Minh City 56
Princeton 52
Ottawa 50
Naples 49
Boardman 42
Munich 42
Los Angeles 41
Tokyo 38
Frankfurt am Main 37
Lawrence 37
Lauterbourg 34
Bologna 33
Medford 31
Pisa 30
Redwood City 30
Hanoi 29
Serra 28
Dearborn 27
Izmir 27
London 27
Nanjing 27
Boulder 25
Istanbul 25
Des Moines 24
Tianjin 24
Bremen 23
Dakar 22
Helsinki 18
Redondo Beach 18
Lancaster 17
São Paulo 17
San Diego 15
Council Bluffs 14
Dong Ket 14
Mumbai 14
Bengaluru 13
Brussels 13
Orem 13
Palermo 13
Parma 13
Turin 13
Buffalo 12
Bari 11
Hangzhou 11
Jaboatão 11
Verona 11
Changsha 10
Guangzhou 10
Salerno 10
Bhavnagar 9
Boston 9
Genoa 9
Trieste 9
Udine 9
Washington 9
Wuhan 9
Acerra 8
Baghdad 8
Chengdu 8
Chicago 8
Columbus 8
Lucca 8
Brescia 7
Cuneo 7
Haiphong 7
Modena 7
Montale 7
Quanzhou 7
San Francisco 7
Shenzhen 7
Cascina 6
Dhaka 6
Fuzhou 6
Jacksonville 6
La Spezia 6
Messina 6
Nanchang 6
Totale 4.915
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.171
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 341
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 289
LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER. 276
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 242
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 234
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 228
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 226
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 220
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 196
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 194
A kinetic study of gamma-glutamyltransferase (GGT)-mediated S-nitrosoglutathione catabolism 190
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 188
A kinetic study of gamma-glutamyltransferase (GGT)-mediated S-nitrosoglutathione catabolism 183
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 178
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 177
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 177
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 173
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 164
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 164
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 161
null 160
null 157
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 155
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 154
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 152
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 148
null 146
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 144
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 141
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 137
WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION 136
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 127
Genetic heterogeneity of Medullary Thyroid Carcinoma 111
Whole Exome Sequencing of Medullary Thyroid Carcinomas did not identify oncogenic drivers alternative to RET and RAS genes 103
SIMULTANEOUS MEDULLARY AND PAPILLARY THYROID CARCINOMAS SHOW INDEPENDENT GENETIC ORIGIN 91
Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. 90
Ret Oncogene and Thyroid Carcinoma 82
null 75
null 70
null 58
Totale 8.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.046
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.046
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022631 23 28 15 57 129 62 23 38 40 15 53 148
2022/20231.034 135 155 71 71 76 96 53 65 180 33 72 27
2023/2024888 93 69 68 62 102 122 84 64 50 39 47 88
2024/20251.636 51 81 50 114 183 177 133 107 148 184 144 264
2025/20261.712 136 207 214 133 171 109 325 99 104 131 58 25
2026/202714 14 0 0 0 0 0 0 0 0 0 0 0
Totale 8.395